Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC Combined With Tislelizumab and Regorafenib for Advanced Cholangiocarcinoma
NCT07619937Phase 2Completed
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jul 2022
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, regorafenib in cholangiocarcinoma (CCA), sponsored by The First Affiliated Hospital of Zhengzhou University. Started Jul 2022; status: completed.
02
Drugs
tislelizumabregorafenib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT07619937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619937.